ArticleResearch square2025

A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety.

James Murrough et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.